PCDHGB7 and neoplasm: The data from the IMvigor210 cohort and Kim cohort showed that patients with high expression of PCDHGB7 in tumor tissue exhibited significantly poor responses to immunotherapy, which may be due to its negative correlation with TMB, as well as its significant correlation with M2 macrophages and Treg cells.